Claims for Patent: 7,951,958

Summary for Patent: 7,951,958

Title:	Imidazole compounds for the treatment of neurodegenerative disorders
Abstract:	The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
Inventor(s):	Michael A. Brodney, Karen J. Coffman
Assignee:	Pfizer Corp SRL
Application Number:	US12/723,204
Patent Claims:	1. A compound of Formula I, wherein: A is absent; R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three substituents independently selected from C1-C6 alkyl, halo, and —OH; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen or C1-C6 alkyl; R4 is hydrogen or C1-C6 alkyl; R6 is hydrogen or C1-C6 alkyl; R7 is C1-C10 alkyl, wherein R7 is optionally substituted with from one to three substituents independently selected from C1-C8 alkoxy, —OH, —NR9R10, —C(═O)NR9 R10, —C(═O)R11, and —C(═O)OR11; and R9, R10, and R11 are each independently selected from hydrogen and C1-C6 alkyl, wherein each hydrogen atom of said C1-C6 alkyl is optionally independently replaced with a halo atom; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1, wherein R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three halo, or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 2, wherein R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three fluorine or chlorine, or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 3, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl or indanyl optionally substituted with from one to three halo, or a pharmaceutically acceptable salt thereof. 5. A compound according to claim 4, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl optionally substituted with from one to three halo, or a pharmaceutically acceptable salt thereof. 6. A compound according to claim 3, wherein R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 7. A compound according to claim 6, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl or indanyl optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 8. A compound according to claim 7, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 9. A compound of Formula I, wherein: A is absent; R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three independently selected halo; R2 is hydrogen or C1-C6 alkyl; R3 is hydrogen, —CH2CH2SCH3, —O(C1-C4)alkyl or C1-C6 alkyl; R4 is hydrogen or C1-C6 alkyl; R6 is hydrogen or C1-C6 alkyl; R7 is C1-C10 alkyl, wherein R7 is optionally substituted with from one to three substituents independently selected from C1-C8 alkoxy, —OH, —NR9R10 , —C(═O)NR9R10, —C(═O)R11, —C(═O)OR11, and (4-6 membered) heterocycloalkyl; and R9, R10, and R11 are each independently selected from hydrogen and C1-C6 alkyl, wherein each hydrogen atom of said C1-C6 alkyl is optionally independently replaced with a halo atom; or a pharmaceutically acceptable salt thereof. 10. A compound according to claim 9, wherein R1 is benzo(C5-C6 cycloalkyl) optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 11. A compound according to claim 10, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl or indanyl optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 12. A compound according to claim 11, wherein R1 is 1,2,3,4-tetrahydronaphthalenyl optionally substituted with from one to three fluorine, or a pharmaceutically acceptable salt thereof. 13. A compound according to claim 9, wherein R7 is C1-C6 alkyl optionally substituted with —NR9R10, morpholinyl, pyrrolidinyl, or piperidinyl, or a pharmaceutically acceptable salt thereof. 14. A compound according to claim 12, wherein R7 is C1-C6 alkyl optionally substituted with —NR9R10, morpholinyl, pyrrolidinyl, or piperidinyl, or a pharmaceutically acceptable salt thereof. 15. A compound according to claim 14, wherein R7 is C1-C6 alkyl optionally substituted with —NR9R10, or a pharmaceutically acceptable salt thereof. 16. A compound according to claim 14, wherein R7 is C1-C6 alkyl substituted with —NR9R10, or a pharmaceutically acceptable salt thereof. 17. A compound according to claim 1, wherein the compound of Formula I has the structure and wherein R2 and R4 are hydrogen, or a pharmaceutically acceptable salt thereof. 18. A compound according to claim 9, wherein the compound of Formula I has the structure and wherein R2 and R4 are hydrogen, or a pharmaceutically acceptable salt thereof. 19. A pharmaceutical composition, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition, comprising an amount of a compound according to claim 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 21. A pharmaceutical composition, comprising an amount of a compound according to claim 17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 22. A pharmaceutical composition, comprising an amount of a compound according to claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.